Gender
Male
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
- Metastatic castration resistant prostate cancer (mCRPC) with histologic confirmation
of adenocarcinoma (adenocarcinoma with small-cell or neuroendocrine features is
allowed) with prior exposure to at least one androgen receptor (AR) targeted therapy
(example, abiraterone acetate, enzalutamide, apalutamide, darolutamide). In addition:
Part 1: prior taxane or other chemotherapy is acceptable but not required. Part 2a:
prior taxane or other chemotherapy required, Part 2b: no prior taxane or other
chemotherapy, Part 2c: mCRPC that has progressed after prior treatment with lutetium
Lu-177 vipivotide tetraxetan
- Prior orchiectomy or medical castration; or, for participants who have not undergone
orchiectomy, must be receiving ongoing androgen deprivation therapy with a
gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the
first dose of study drug and must continue this therapy throughout the treatment phase
- Palliative radiotherapy (for example [eg], soft tissue lesions) must be completed
greater than (>) 2 weeks prior to start of study drug except for palliative
radiotherapy for pain (eg, bone pain), which may be used any time prior to first dose
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ functions as reflected in laboratory parameters
Exclusion Criteria:
- Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, samarium, or other
radioconjugate therapy. In addition: Part 2b: Prior treatment with chemotherapy (eg,
docetaxel) or poly ADP ribose polymerase (PARP) inhibitors. Part 2c: Prior treatment
with lutetium Lu-177 vipivotide tetraxetan is permitted
- Known history of myelodysplastic syndrome, leukemia, or hematological malignancy with
features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any
timepoint
- Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade
less than or equal to (<=) 1 (except alopecia, radiation tissue fibrosis, or
peripheral neuropathy)
- Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients
and protein therapeutics
- Active or chronic hepatitis B or hepatitis C infection
